Health Canada Authorizes Vabysmo® (faricimab injection) Pre-Filled Syringe (PFS) for Three Leading Causes of Vision Loss

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that Health Canada has authorized Vabysmo® (faricimab injection) for use in a 6.0 mg single-use pre-filled syringe (PFS) for use in the treatment of wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema secondary to retinal vein occlusion (RVO).1 These leading causes of vision loss affect around 70 million people worldwide and can have a serious impact on patients, their fa